Nasus Pharma announces annual, special shareholder meeting
NSRX•Shareholder meeting scheduled for Oct. 8, 2026
Nasus Pharma will hold its annual and special general meeting of shareholders in Tel Aviv, Israel, on Oct. 8, 2026.
Votes will cover reappointing Deloitte Israel as independent auditor, with the board set to determine remuneration.
Executive compensation and director reappointments on the agenda
Shareholders will also vote on reappointing directors David Silberman and Sharon Shacham for new three-year terms.
Items include approval of CEO Brendan P. O’Grady’s compensation package, including a US$500,000 base salary and up to 280,000 options.
Additional votes include a US$70,000 one-time bonus for former CEO Dan Teleman, plus a higher share reserve for incentive stock options.
